{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:38:50Z","timestamp":1758587930195,"version":"3.44.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.therap.2020.02.016","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T13:33:56Z","timestamp":1582292036000},"page":"252-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tobramycine eye drops and ocular myasthenia gravis reactivation: A case report"],"prefix":"10.1016","volume":"76","author":[{"given":"Claire","family":"de Canecaude","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Gazagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Paraire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.02.016_bib0045","series-title":"Aminoglycosides. Goodman and Gilman's the pharmacological basis of therapeutics","first-page":"1039","author":"MacDougall","year":"2018"},{"key":"10.1016\/j.therap.2020.02.016_bib0050","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/j.1875-9114.1997.tb03085.x","article-title":"Drug-induced neuromuscular blockade and myasthenia gravis","volume":"17","author":"Barrons","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2020.02.016_bib0055","first-page":"CD005081","article-title":"Medical and surgical treatment for ocular myasthenia","volume":"12","author":"Benatar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2020.02.016_bib0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ncl.2016.08.008","article-title":"Update on ocular myasthenia gravis","volume":"35","author":"Smith","year":"2017","journal-title":"Neurol Clin"},{"key":"10.1016\/j.therap.2020.02.016_bib0065","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2020.02.016_bib0070","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance. The next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2020.02.016_bib0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Info J"},{"key":"10.1016\/j.therap.2020.02.016_bib0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.therap.2018.05.002","article-title":"Is the collecting activity of regional pharmacovigilance centers influenced by regional demographic or health determinants?","volume":"74","author":"Lam","year":"2019","journal-title":"Therapies"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:20Z","timestamp":1758567260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720300305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0040595720300305"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.016","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tobramycine eye drops and ocular myasthenia gravis reactivation: A case report","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}